Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
steroids, progestogens	1962	68-22-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: norethindrone norethisteron norethisterone norethynodrone	A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION. Molecular weight: 298.43 Formula: C20H26O2 CLOGP: 2.79 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 37.30 ALOGS: -4.65 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

norethindrone
norethisteron
norethisterone
norethynodrone

A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION.

Molecular weight: 298.43
Formula: C20H26O2
CLOGP: 2.79
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 37.30
ALOGS: -4.65
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2.50	mg	P
5	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.01 mg/mL	Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine)	2 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.02 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	64 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	3.257		Moderate	0.73
caco2-efflux	Caco-2 efflux ratio (BA/AB)	0.381		Moderate	0.73
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	72.946	10^-6 cm/s	Moderate	0.73
dh-clint	Dog hepatocyte intrinsic clearance	28.184	uL/min/10^6 cells	Moderate	0.73
dppb	Dog plasma protein binding (% unbound)	6.610	%	Moderate	0.73
fcs-ppb	Fetal calf serum protein binding (% unbound)	9.780	%	Moderate	0.73
herg	hERG pIC50	4.843	pIC50	Moderate	0.73
hh-clint	Human hepatocyte intrinsic clearance	3.750	uL/min/10^6 cells	Moderate	0.73
hlm-clint	Human liver microsomal intrinsic clearance	21.827	uL/min/mg protein	Moderate	0.73
hppb	Human plasma protein binding (% unbound)	4.690	%	Moderate	0.73
kinase-safety-class	ACVR2B,AXL,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK	17
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.197		Moderate	0.73
mh-clint	Mouse hepatocyte intrinsic clearance	69.663		Moderate	0.73
mppb	Mouse plasma protein binding (% unbound)	6.650		Moderate	0.73
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	3.373		Moderate	0.73
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pppb	Pig plasma protein binding (% unbound)	7.880	%	Moderate	0.73
rh-clint	Rat hepatocyte intrinsic clearance	55.081	uL/min/10^6 cells	Moderate	0.73
rh-fuinc	Rat hepatocyte fraction unbound in incubation	33.440	%	Moderate	0.73
rppb	Rat plasma protein binding (% unbound)	5.880	%	Moderate	0.73
solubility-dd	Solubility at pH 7.4 in DMSO	44.771	uM	Moderate	0.73

Approvals:

Date	Agency	Company	Orphan
May 21, 1962	FDA	ORTHO MCNEIL PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic adenoma	210.27	17	36	7938	403	90620070
Vaginal haemorrhage	118.70	17	57	7917	31214	90589259
Prostatic disorder	75.76	17	11	7963	36	90620437
Aplastic anaemia	68.61	17	30	7944	13239	90607234
Heavy menstrual bleeding	64.74	17	33	7941	20497	90599976
Intermenstrual bleeding	61.54	17	25	7949	9198	90611275
Endometriosis	56.08	17	21	7953	6227	90614246
Superior sagittal sinus thrombosis	49.65	17	12	7962	794	90619679
Metaplasia	49.34	17	11	7963	510	90619963
Pelvic pain	46.43	17	24	7950	15333	90605140
Cerebral venous sinus thrombosis	45.08	17	14	7960	2362	90618111
Purpura	44.41	17	23	7951	14755	90605718
Pregnancy on oral contraceptive	41.02	17	11	7963	1104	90619369
Transfusion	40.77	17	23	7951	17465	90603008
Product dose omission issue	36.81	17	80	7894	291607	90328866
Complication of device insertion	33.55	17	17	7957	10419	90610054
Ovarian atrophy	33.22	17	6	7968	93	90620380
Febrile neutropenia	33.19	17	54	7920	158295	90462178
Exposure to allergen	32.92	17	8	7966	542	90619931
Uterine perforation	32.43	17	15	7959	7539	90612934
Haemorrhage	30.55	17	34	7940	69335	90551138
Nasal mucosal discolouration	29.99	17	5	7969	47	90620426
Hot flush	29.42	17	31	7943	59457	90561016
Rash maculo-papular	27.07	17	25	7949	40908	90579565
Hereditary angioedema	26.49	17	14	7960	9351	90611122
Device dislocation	26.38	17	22	7952	31460	90589013
Menstruation irregular	25.53	17	13	7961	8047	90612426
Rash erythematous	25.44	17	30	7944	65074	90555399
Genital burning sensation	25.32	17	6	7968	365	90620108
Blood iron decreased	24.98	17	17	7957	17942	90602531
Mucosal inflammation	24.95	17	28	7946	57597	90562876
Vaginal ulceration	24.14	17	6	7968	446	90620027
Acne	24.05	17	20	7954	28487	90591986
Throat tightness	23.46	17	20	7954	29464	90591009
Pulmonary embolism	21.39	17	40	7934	130780	90489693
Hepatic rupture	21.09	17	4	7970	82	90620391
Dilatation intrahepatic duct acquired	20.99	17	6	7968	762	90619711
Lip exfoliation	20.97	17	6	7968	764	90619709
Ovarian cyst	20.84	17	15	7959	17303	90603170
Melaena	20.62	17	20	7954	34777	90585696
Ovarian failure	20.31	17	7	7967	1636	90618837
Product administration interrupted	20.22	17	13	7961	12479	90607994
Haemoglobin decreased	19.91	17	44	7930	161912	90458561
Peliosis hepatis	19.32	17	4	7970	130	90620343
Drug-induced liver injury	19.18	17	31	7943	90287	90530186
Dermatitis atopic	18.84	17	16	7958	23456	90597017
Haemorrhagic tumour necrosis	18.43	17	3	7971	24	90620449
Abortion spontaneous	18.03	17	23	7951	54033	90566440
Headache	17.70	17	133	7841	862613	89757860
Systemic lupus erythematosus	17.63	17	5	7969	361891	90258582
Migraine	17.27	17	46	7928	190346	90430127
Treatment failure	17.21	17	3	7971	303925	90316548

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic adenoma	222.80	18.02	36	6422	431	110582410
Vaginal haemorrhage	131.73	18.02	51	6407	25023	110557818
Metaplasia	125.26	18.02	23	6435	604	110582237
Prostatic disorder	93.48	18.02	23	6435	2486	110580355
Intermenstrual bleeding	62.36	18.02	21	6437	6913	110575928
Heavy menstrual bleeding	60.89	18.02	26	6432	16339	110566502
Aplastic anaemia	59.97	18.02	29	6429	24279	110558562
Superior sagittal sinus thrombosis	50.28	18.02	12	6446	1141	110581700
Cerebral venous sinus thrombosis	43.63	18.02	13	6445	2882	110579959
Complication of device insertion	42.95	18.02	17	6441	8821	110574020
Pregnancy on oral contraceptive	42.24	18.02	10	6448	918	110581923
Transfusion	41.51	18.02	23	6435	25449	110557392
Purpura	39.68	18.02	22	6436	24366	110558475
Pelvic pain	39.26	18.02	19	6439	15923	110566918
Uterine perforation	36.21	18.02	14	6444	6826	110576015
Exposure to allergen	35.97	18.02	8	6450	557	110582284
Ovarian atrophy	35.93	18.02	6	6452	89	110582752
Endometriosis	34.57	18.02	12	6446	4322	110578519
Nasal mucosal discolouration	29.82	18.02	5	6453	76	110582765
Vaginal ulceration	29.14	18.02	6	6452	289	110582552
Blood iron decreased	27.66	18.02	16	6442	19198	110563643
Genital burning sensation	27.18	18.02	6	6452	403	110582438
Drug-induced liver injury	26.75	18.02	34	6424	120033	110462808
Ovarian failure	26.74	18.02	7	6451	969	110581872
Throat tightness	26.18	18.02	19	6439	33470	110549371
Haemorrhagic tumour necrosis	25.14	18.02	4	6454	43	110582798
Device dislocation	24.81	18.02	18	6440	31686	110551155
Rash erythematous	24.57	18.02	27	6431	81805	110501036
Acne	23.92	18.02	18	6440	33502	110549339
Lip exfoliation	23.33	18.02	6	6452	774	110582067
Dilatation intrahepatic duct acquired	22.87	18.02	6	6452	837	110582004
Product dose omission issue	20.84	18.02	53	6405	321729	110261112
Device expulsion	20.74	18.02	16	6442	30875	110551966
Hepatic rupture	20.48	18.02	4	6454	147	110582694
Medical device pain	19.82	18.02	6	6452	1404	110581437
Rash maculo-papular	19.75	18.02	23	6435	74199	110508642
Escherichia urinary tract infection	19.47	18.02	12	6446	16150	110566691
Peliosis hepatis	19.42	18.02	4	6454	193	110582648
Haemorrhage	18.86	18.02	27	6431	106665	110476176
Migraine	18.84	18.02	35	6423	171617	110411224
Administration site rash	18.79	18.02	3	6455	33	110582808
Headache	18.69	18.02	101	6357	882276	109700565
Ovarian cyst	18.47	18.02	11	6447	13919	110568922
Toxicity to various agents	18.40	18.02	3	6455	480552	110102289
Death	18.28	18.02	9	6449	698860	109883981
Haemoglobin decreased	18.26	18.02	43	6415	248684	110334157

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	G03AA05	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, fixed combinations
ATC	G03AB04	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens and estrogens, sequential preparations
ATC	G03AC01	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE Progestogens
ATC	G03DC02	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS Estren derivatives
ATC	G03FA01	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, fixed combinations
ATC	G03FB05	GENITO URINARY SYSTEM AND SEX HORMONES SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM PROGESTOGENS AND ESTROGENS IN COMBINATION Progestogens and estrogens, sequential preparations
ATC	H01CC53	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Anti-gonadotropin-releasing hormones
ATC	H01CC54	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES HYPOTHALAMIC HORMONES Anti-gonadotropin-releasing hormones
FDA CS	M0447349	Progesterone Congeners
FDA Chemical/Ingredient	N0000011301	Progesterone Congeners
MeSH PA	D000080066	Contraceptive Agents, Hormonal
MeSH PA	D003271	Contraceptive Agents, Female
MeSH PA	D003278	Contraceptives, Oral, Hormonal
MeSH PA	D003280	Contraceptives, Oral, Synthetic
MeSH PA	D012102	Reproductive Control Agents
FDA EPC	N0000175602	Progestin
CHEBI has role	CHEBI:22587	antiviral agent
CHEBI has role	CHEBI:35480	analgesic
CHEBI has role	CHEBI:35610	antineoplastic agent
CHEBI has role	CHEBI:35705	immunosuppressive agent
CHEBI has role	CHEBI:49326	synthetic oral contraceptive
CHEBI has role	CHEBI:59826	progestin

Related Drugs by ATC class:

G03AA Progestogens and estrogens, fixed combinations 17 drugs

chlormadinone desogestrel dienogest drospirenone estetrol estradiol ethinylestradiol etynodiol gestodene levonorgestrel lynestrenol medroxyprogesterone show all 17 →

G03AB Progestogens and estrogens, sequential preparations 10 drugs

chlormadinone desogestrel dienogest estradiol ethinylestradiol gestodene levonorgestrel lynestrenol megestrol acetate norgestimate

G03AC Progestogens 9 drugs

desogestrel drospirenone etonogestrel levonorgestrel lynestrenol medroxyprogesterone megestrol acetate norgestrienone quingestanol acetate

G03DC Estren derivatives 5 drugs

allylestrenol ethisterone etynodiol lynestrenol methylestrenolone

G03FA Progestogens and estrogens, fixed combinations 15 drugs

dienogest drospirenone dydrogesterone ethisterone etynodiol hydroxyprogesterone caproate levonorgestrel lynestrenol medroxyprogesterone megestrol acetate methylestrenolone norethynodrel show all 15 →

G03FB Progestogens and estrogens, sequential preparations 10 drugs

chlormadinone desogestrel dydrogesterone levonorgestrel lynestrenol medrogestone medroxyprogesterone megestrol acetate nomegestrol trimegestone

H01CC Anti-gonadotropin-releasing hormones 6 drugs

cetrorelix elagolix estradiol ganirelix linzagolix relugolix

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Contraception	indication	13197004
Female hypogonadism syndrome	indication	16041008
Dysfunctional uterine bleeding	indication	19155002
Atrophic vaginitis	indication	52441000
Primary ovarian failure	indication	65846009
Secondary physiologic amenorrhea	indication	86030004
Acne vulgaris	indication	88616000
Postmenopausal osteoporosis	indication	102447009
Vasomotor symptoms associated with climacteric disturbance	indication	123756000
Endometriosis	indication	129103003
Menopausal flushing	indication	198436008
Atrophic vulva	indication	248861000	DOID:14275
Menorrhagia	indication	386692008
Controlled ovarian stimulation	indication	732970000
Vasomotor symptoms associated with ovarian deficiency symptoms	indication
Amenorrhea	off-label use	14302001	DOID:13938
Polycystic ovaries	off-label use	69878008
Dysmenorrhea	off-label use	266599000
Abnormal uterine bleeding unrelated to menstrual cycle	off-label use	312984006
Heart valve disorder	contraindication	368009	DOID:4079
Hyperlipoproteinemia	contraindication	3744001	DOID:1168
Hypocalcemia	contraindication	5291005
Hypercholesterolemia	contraindication	13644009
Myocardial infarction	contraindication	22298006	DOID:5844
Depressive disorder	contraindication	35489007
Chloasma	contraindication	36209000
Migraine	contraindication	37796009	DOID:6364
Hypertensive disorder	contraindication	38341003	DOID:10763
Disorder of gallbladder	contraindication	39621005	DOID:0060262
Hypothyroidism	contraindication	40930008	DOID:1459
Body fluid retention	contraindication	43498006
Thrombosis of retinal vein	contraindication	46085004
Humoral hypercalcemia of malignancy	contraindication	47709007
Chronic heart failure	contraindication	48447003
Dementia	contraindication	52448006
Hepatic porphyria	contraindication	55056006	DOID:3133
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Hyperlipidemia	contraindication	55822004	DOID:1168
Benign mammary dysplasia	contraindication	57993004
Obstructive hyperbilirubinemia	contraindication	59848001
Thrombophlebitis	contraindication	64156001	DOID:3875
Intermenstrual bleeding - irregular	contraindication	64996003
Diabetes mellitus	contraindication	73211009	DOID:9351
Hyperglycemia	contraindication	80394007	DOID:4195
Epilepsy	contraindication	84757009	DOID:1826
Breast lump	contraindication	89164003
Kidney disease	contraindication	90708001	DOID:557
Malignant neoplasm of liver	contraindication	93870000	DOID:3571
Uterine leiomyoma	contraindication	95315005	DOID:13223
Deep venous thrombosis	contraindication	128053003
Liver function tests abnormal	contraindication	166603001
Mammography abnormal	contraindication	168750009
Angina pectoris	contraindication	194828000
Asthma	contraindication	195967001	DOID:2841
Cerebrovascular accident	contraindication	230690007
Pulmonary thromboembolism	contraindication	233935004
Thrombophilia	contraindication	234467004	DOID:2452
Disease of liver	contraindication	235856003	DOID:409
Cholestasis of pregnancy	contraindication	235888006
Endometrial carcinoma	contraindication	254878006	DOID:2871
Chorea	contraindication	271700006
Pregnancy, function	contraindication	289908002
Hypertriglyceridemia	contraindication	302870006
Functional visual loss	contraindication	313165001
Malignant tumor of cervix	contraindication	363354003	DOID:4362
Malignant tumor of ovary	contraindication	363443007	DOID:2394
Thromboembolic disorder	contraindication	371039008
Cardiovascular event risk	contraindication	395112001
Disorder of coronary artery	contraindication	414024009
Obesity	contraindication	414916001	DOID:9970
Estrogen receptor positive tumor	contraindication	416053008
Porphyria	contraindication	418470004
Optic disc edema	contraindication	423341008	DOID:146
Family history of malignant neoplasm of breast	contraindication	429740004
Hypertensive urgency	contraindication	443482000
Carcinoma of female breast	contraindication	447782002
Smokes tobacco daily	contraindication	449868002
Nonspecific Abnormal Papanicolaou Smear of Cervix	contraindication
Major Surgery with Prolonged Post-Operative Immobilization	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Progesterone receptor	Nuclear hormone receptor	P06401	PRGR_HUMAN	AGONIST	ED50	11.26	WOMBAT-PK	CHEMBL
Glucocorticoid receptor	Nuclear hormone receptor	P04150	GCR_HUMAN		Ki	6.71	DRUG MATRIX
Estrogen receptor	Nuclear hormone receptor	P03372	ESR1_HUMAN		Ki	6.64	DRUG MATRIX
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN		IC50	7.12	WOMBAT-PK
Sex hormone-binding globulin	Secreted	P04278	SHBG_HUMAN		Kd	7.97	CHEMBL
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.62	DRUG MATRIX
Androgen receptor	Transcription factor		ANDR_RAT		IC50	6.92	CHEMBL
Progesterone receptor	Transcription factor		Q690N0_BOVIN		Ki	8.91	DRUG MATRIX
Estrogen receptor	Transcription factor		ESR1_RAT ESR2_RAT		Kd	9.20	CHEMBL

External reference:

ID	Source
4018496	VUID
N0000146818	NUI
D00182	KEGG_DRUG
4018496	VANDF
C0028356	UMLSCUI
CHEBI:7627	CHEBI
CHEMBL1162	ChEMBL_ID
DB00717	DRUGBANK_ID
2880	IUPHAR_LIGAND_ID
6230	PUBCHEM_CID
7514	RXNORM
182290	MMSL
5187	MMSL
d00555	MMSL
001298	NDDF
001326	NDDF
126102009	SNOMEDCT_US
63758001	SNOMEDCT_US
D009640	MESH_DESCRIPTOR_UI
NDR	PDB_CHEM_ID
687	INN_ID
T18F433X4S	UNII
T18F433X4S	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
NORETHINDRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7292	TABLET	0.35 mg	ORAL	ANDA	14 sections
NORETHINDRONE	HUMAN PRESCRIPTION DRUG LABEL	1	0378-7292	TABLET	0.35 mg	ORAL	ANDA	14 sections
Nora BE	HUMAN PRESCRIPTION DRUG LABEL	1	0480-3475	TABLET	0.35 mg	ORAL	NDA authorized generic	21 sections
Nortrel21 Day	HUMAN PRESCRIPTION DRUG LABEL	2	0555-9009	TABLET	1 mg	ORAL	ANDA	21 sections
NORETHINDRONE	HUMAN PRESCRIPTION DRUG LABEL	1	50090-6161	TABLET	0.35 mg	ORAL	ANDA	13 sections
LYZA	HUMAN PRESCRIPTION DRUG LABEL	1	50102-100	TABLET	0.35 mg	ORAL	ANDA	13 sections
Lyleq	Human Prescription Drug Label	1	50102-300	TABLET	0.35 mg	ORAL	ANDA	14 sections
NORLYROC	HUMAN PRESCRIPTION DRUG LABEL	1	51660-127	TABLET, FILM COATED	0.35 mg	ORAL	ANDA	12 sections
CAMILA	HUMAN PRESCRIPTION DRUG LABEL	1	51862-884	TABLET	0.35 mg	ORAL	ANDA	25 sections
ERRIN	HUMAN PRESCRIPTION DRUG LABEL	1	51862-886	TABLET	0.35 mg	ORAL	ANDA	26 sections
Lyleq	Human Prescription Drug Label	1	53002-1793	TABLET	0.35 mg	ORAL	ANDA	14 sections
MICRONOR	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4369	TABLET	0.35 mg	ORAL	NDA	14 sections
Camila	HUMAN PRESCRIPTION DRUG LABEL	1	54868-4814	TABLET	0.35 mg	ORAL	ANDA	15 sections
Emzahh	Human Prescription Drug Label	1	59651-136	TABLET	0.35 mg	ORAL	ANDA	21 sections
Norethindrone	HUMAN PRESCRIPTION DRUG LABEL	1	60505-4900	TABLET	0.35 mg	ORAL	ANDA	19 sections
Norethindrone	HUMAN PRESCRIPTION DRUG LABEL	1	63187-748	TABLET	0.35 mg	ORAL	ANDA	24 sections
Incassia	Human Prescription Drug Label	1	65862-925	TABLET	0.35 mg	ORAL	ANDA	14 sections
NORETHINDRONE	HUMAN PRESCRIPTION DRUG LABEL	1	68180-876	TABLET	0.35 mg	ORAL	ANDA	13 sections
Jencycla	HUMAN PRESCRIPTION DRUG LABEL	1	68180-877	TABLET	0.35 mg	ORAL	ANDA	14 sections
HEATHER	HUMAN PRESCRIPTION DRUG LABEL	1	68462-303	TABLET	0.35 mg	ORAL	ANDA	23 sections
Norethindrone	HUMAN PRESCRIPTION DRUG LABEL	1	68462-305	TABLET	0.35 mg	ORAL	ANDA	24 sections
Orquidea	HUMAN PRESCRIPTION DRUG LABEL	1	70700-316	TABLET	0.35 mg	ORAL	ANDA	14 sections
MELEYA	HUMAN PRESCRIPTION DRUG LABEL	1	70700-317	TABLET	0.35 mg	ORAL	ANDA	14 sections
ERRIN	HUMAN PRESCRIPTION DRUG LABEL	1	71205-526	TABLET	0.35 mg	ORAL	ANDA	24 sections
Norethindrone	HUMAN PRESCRIPTION DRUG LABEL	1	72789-439	TABLET	0.35 mg	ORAL	ANDA	14 sections
CAMILA	HUMAN PRESCRIPTION DRUG LABEL	1	75907-074	TABLET	0.35 mg	ORAL	ANDA	25 sections
ERRIN	HUMAN PRESCRIPTION DRUG LABEL	1	75907-075	TABLET	0.35 mg	ORAL	ANDA	26 sections
Norethindrone	HUMAN PRESCRIPTION DRUG LABEL	1	76413-118	TABLET	0.35 mg	ORAL	ANDA	14 sections
Affodel	HUMAN PRESCRIPTION DRUG LABEL	1	79929-015	TABLET	0.35 mg	ORAL	ANDA	19 sections
NORETHINDRONE	HUMAN PRESCRIPTION DRUG LABEL	1	82804-175	TABLET	0.35 mg	ORAL	ANDA	13 sections

Ask DrugCentral

Try a sample question

norethisterone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: